Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Liabilities and Shareholders Equity: 2012-2025

Historic Liabilities and Shareholders Equity for Ascendis Pharma A (ASND) over the last 11 years, with Sep 2025 value amounting to $1.3 billion.

  • Ascendis Pharma A's Liabilities and Shareholders Equity rose 12.38% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 billion, marking a year-over-year increase of 31.25%. This contributed to the annual value of $1.3 billion for FY2024, which is 43.72% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Liabilities and Shareholders Equity stood at $1.3 billion, which was up 9.62% from $1.2 billion recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Liabilities and Shareholders Equity high stood at $1.5 billion for Q1 2022, and its period low was $816.6 million during Q2 2024.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.1 billion, with a median of $1.0 billion in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 69.74% in 2021, then plummeted by 36.64% in 2023.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Liabilities and Shareholders Equity stood at $1.2 billion in 2021, then fell by 10.42% to $1.1 billion in 2022, then fell by 20.10% to $888.3 million in 2023, then skyrocketed by 41.89% to $1.3 billion in 2024, then rose by 12.38% to $1.3 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.3 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.1 billion for Q1 2025.